Alcohol Biomarkers In Post Liver Transplant Patients

肝移植后患者的酒精生物标志物

• 批准号: 8133325
• 负责人: MICHAEL F. FLEMING
• 金额: $ 17.57万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-20 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8133325
• 关键词: Alcohol abuse; Alcohol consumption; Alcoholic Liver Diseases; Alcohols; Area; Attention Deficit Disorder; Award; Biological Assay; Biological Markers; Blood alcohol level measurement; Chicago; Child; Clinical Research; Clinical and Translational Science Awards; Commit; Control Groups; Counseling; Data; Dependence; Detection; Diagnosis; Doctor of Philosophy; Early Diagnosis; Education; Europe; Faculty; Family; Family Practice; Family member; Fetal Alcohol Spectrum Disorder; Frequencies; Fright; Funding; Goals; Grant; High Pressure Liquid Chromatography; Hospitalization; Infection; Injury; Injury to Liver; Institute of Medicine (U.S.); Interview; Liver; Liver Failure; Liver diseases; Measures; Medical; Medical Records; Medicine; Mentored Patient-Oriented Research Career Development Award; Mentors; Methylphenidate; Minnesota; Monitor; Operative Surgical Procedures; Organ Procurements; Organ Transplantation; Paper; Patient Recruitments; Patient Self-Report; Patients; Pediatrics; Physicians; Postdoctoral Fellow; Publishing; Recording of previous events; Recruitment Activity; Relapse; Reporting; Research; Research Activity; Research Personnel; Research Support; Risk; Risk Factors; SECTM1 gene; Sampling; Scientist; Shame; South Carolina; Students; Substance abuse problem; Testing; Time; Training Activity; Translational Research; Transplant Recipients; Transplantation; Trauma; United States; United States National Academy of Sciences; Universities; Validity and Reliability; Wages; Whole Blood; Wisconsin; Work; Writing; alcohol research; binge drinking; carbohydrate-deficient transferrin; career; cost; design; drinking; drug craving; efficacy testing; experience; liver transplantation; medical specialties; performance tests; phosphatidylethanol; prevent; professor; programs; prospective; public health relevance; research study; success; working group

DESCRIPTION (provided by applicant): The goal of this mid-career K24 application is to support the mentoring and research activities of Dr. Michael Fleming. He is committed to continuing an active research program in clinical and translational research. This grant is a competitive renewal that was initially funded in September 2005 and will end in September 2010. He is asking for an additional 5 years of funding. Dr. Fleming successfully completed the two research studies proposed in the initial application, participated in training activities and mentored PhD students, post doctoral fellows and faculty. During the period of the award he was elected to the National Academy of Sciences Institute of Medicine for his alcohol research and mentoring. He is also a national leader among the CTSA (Clinical Translational Science Award) programs and is the chair elect of the national CTSA Education Key Function Committee and Mentor Working Group. Work completed with current K24 grant: The first study evaluated two alcohol biomarkers, Blood Alcohol Levels and Carbohydrate-Deficient Transferrin (CDT), in a sample 214 patients admitted for trauma. The second study tested the efficacy of methylphenidate in a sample 13 children with a diagnosis of Attention Deficit Disorder and Fetal Alcohol Spectrum Disorder. Since 2005 his research group and trainees have published 42 research papers in the substance abuse area. Co-authors of these papers include five students, nine physician post doctoral research fellows, 11 University of Wisconsin-Madison physician faculty and scientists from 12 non-UW research groups. Over the last four years six of his trainees have been awarded K23/K08/K12/K01/R21/R03 grants, one MD PhD student was awarded an F30 and another PhD student an F31 grant. Without the salary and research support provided by the K24 grant much of this work and the success of his trainees would not have been possible. Proposed work for the K24 renewal: The K24 renewal will provide protected time for Dr. Fleming to mentor seven assistant professors in the departments of medicine, pediatrics and family medicine and facilitate his ability to write papers with trainees from three recently completed R01's. He will also initiate a prospective alcohol biomarker study that will test the predictive validity and reliability of Phosphatidylethanol (PEth) and CDT in a sample of 250 post liver transplant patients. Subjects will be recruited from four transplant centers. The biomarkers will be compared to patient self-report, family member interview and transplant staff concerns as well as medical records data. PEth and CDT will be measured at six-month intervals for one year. Significance: The K24 is critical for Dr. Fleming's continued ability to mentor new investigators in alcohol research and for his research on alcohol biomarkers. PUBLIC HEALTH RELEVANCE: The goal of the study is to find out if a lab test can tell which patients are drinking alcohol after having a liver transplant. A positive study would help physicians identify and treat patients before they damage their new liver.

描述（由申请人提供）：此职业中期 K24 申请的目标是支持 Michael Fleming 博士的指导和研究活动。他致力于继续开展临床和转化研究方面的积极研究计划。这笔赠款是一项竞争性续签，最初于 2005 年 9 月提供，将于 2010 年 9 月结束。他要求再提供 5 年的资助。弗莱明博士成功完成了最初申请中提出的两项研究，参加了培训活动并指导了博士生、博士后研究员和教师。获奖期间，他因其酒精研究和指导而被选入美国国家科学院医学研究所。他还是 CTSA（临床转化科学奖）项目的全国领导者，并且是全国 CTSA 教育关键职能委员会和导师工作组的候任主席。利用当前 K24 拨款完成的工作：第一项研究以 214 名因外伤入院的患者为样本，评估了两种酒精生物标志物、血液酒精水平和碳水化合物缺乏转铁蛋白 (CDT)。第二项研究测试了 13 名被诊断患有注意力缺陷障碍和胎儿酒精谱系障碍的儿童样本中哌醋甲酯的疗效。自 2005 年以来，他的研究小组和学员已发表了 42 篇药物滥用领域的研究论文。这些论文的共同作者包括 5 名学生、9 名医师博士后研究员、11 名威斯康星大学麦迪逊分校医师教员以及来自 12 个非威斯康星大学麦迪逊分校研究小组的科学家。在过去的四年里，他的六名学员获得了 K23/K08/K12/K01/R21/R03 补助金，一名医学博士生获得了 F30 补助金，另一名博士生获得了 F31 补助金。如果没有 K24 拨款提供的工资和研究支持，这项工作的大部分内容和他的学员的成功都是不可能的。 K24 续签的拟议工作：K24 续签将为 Fleming 博士提供受保护的时间，以指导医学、儿科和家庭医学系的七名助理教授，并提高他与最近完成的 R01 的三名学员一起撰写论文的能力。他还将启动一项前瞻性酒精生物标志物研究，该研究将在 250 名肝移植后患者的样本中测试磷脂酰乙醇 (PEth) 和 CDT 的预测有效性和可靠性。受试者将从四个移植中心招募。生物标志物将与患者自我报告、家属访谈、移植工作人员的担忧以及医疗记录数据进行比较。 PEth 和 CDT 将在一年内每六个月进行一次测量。意义：K24 对于弗莱明博士能否持续指导酒精研究新研究者以及酒精生物标志物研究至关重要。 公共健康相关性：该研究的目的是查明实验室测试是否可以判断哪些患者在肝移植后饮酒。一项积极的研究将有助于医生在患者的新肝脏受损之前识别并治疗他们。